this piece corresponds to the legacy myPDB login in the form of a bootstrap modal, will likely retire-->



CWB is found in 1 entry

CWB as free ligands, exist in 1 entry. Example includes: 2YME

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC18 H24 N4 O
Molecular Weight312.41 g/mol
Isomeric SMILESCN1[C@H]2CCC[C@@H]1C[C@@H](C2)NC(=O)c1nn(C)c2ccccc12

Chemical Details

Formal Charge0
Atom Count47
Chiral Atom Count2
Chiral AtomsC03,C07
Bond Count50
Aromatic Bond Count10
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00889 Different stereochemistry
  • approved
  • investigational
DescriptionA serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]
  • granisétron
  • granisetrón
  • granisetronum
SaltsGranisetron hydrochloride
Brand Names
  • Apo-granisetron
  • Granisetron
  • Granisetron Hydrochloride
  • Granisetron Hydrochloride Injection
  • Granisetro
Affected OrganismHumans and other mammals
IndicationFor the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
PharmacologyGranisetron is a selective inhibitor of type 3 serotonergic (5-HT<sub>3</sub>) receptors. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT<sub>3</sub> receptors. The serontonin 5-HT<sub>3</sub> receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.
Mechanism of actionGranisetron is a potent, selective antagonist of 5-HT<sub>3</sub> receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Route of administration
  • Intravenous
  • Oral
  • Subcutaneous
  • Transdermal
  • Alimentary Tract and Metabolism
  • Antiemetics
  • Antiemetics and Antinauseants
  • Antiemetics Antagonists
  • Autonomic Agents
CAS number109889-09-0
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682